US2013330332A1PendingUtilityA1

Treatment of pemphigus

64
Assignee: BIOGEN IDEC INCPriority: May 7, 1999Filed: Aug 16, 2013Published: Dec 12, 2013
Est. expiryMay 7, 2019(expired)· nominal 20-yr term from priority
Inventors:John G. CurdAntonio J. Grillo-Lopez
A61P 9/08A61P 37/00A61P 9/10A61P 7/00A61P 3/10A61P 37/02A61P 9/00A61P 5/14A61P 9/14A61P 7/04A61P 7/06A61P 37/06A61P 43/00A61P 9/12A61P 5/00A61P 29/00A61P 25/00A61P 27/02A61P 35/00A61P 31/06Y10S424/81A61K 31/365C07K 16/2803Y10S424/801A61K 2039/505A61P 19/02C07K 2317/24A61P 13/12A61K 2039/54A61K 39/3955A61P 17/06A61K 47/6849A61K 45/06A61P 21/00C07K 16/2887A61P 17/04A61P 11/06A61K 51/1027A61P 17/02A61P 1/04A61P 17/00A61P 11/00A61K 31/56A61P 11/16A61P 21/04A61P 1/00A61P 13/02A61K 39/395
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention concerns treatment of pemphigus with an antibody which binds to CD20.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating pemphigus in a human comprising administering to the human a therapeutically effective amount of an antibody that binds human CD20. 
     
     
         2 . A method of treating pemphigus in a human comprising administering to the human a therapeutically effective amount of rituximab. 
     
     
         3 . The method of  claim 2  further comprising administering other compounds to the human, wherein the other compounds are coadministered or consecutively administered in either order with the rituximab, and wherein the other compounds are selected from the group consisting of immunosuppressive agents and chemotherapeutic agents. 
     
     
         4 . The method of  claim 3  wherein the immunosuppressive agent is steroid and the chemotherapeutic agent is mycophenolic acid. 
     
     
         5 . The method of  claim 2  wherein the human does not have cancer. 
     
     
         6 . The method of  claim 2  wherein the rituximab is administered intravenously. 
     
     
         7 . The method of  claim 6  wherein the administration of rituximab consists of intravenous administration. 
     
     
         8 . The method of  claim 7  wherein more than one intravenous dose of rituximab is administered. 
     
     
         9 . A method of treating pemphigus in a human comprising administering to the human a therapeutically effective amount of rituximab and further comprising administering to the human other compounds selected from the group consisting of steroid and mycophenolic acid, wherein the other compounds are coadministered or consecutively administered in either order with the rituximab.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.